Synergistic effects between Staphylococcal enterotoxin type B and Monophosphoryl lipid A against mouse fibrosarcoma

Journal of B.U.ON.

Volumn 15, Issue 2, 2010, Pages 340-347

  Imani Fooladi, A A ^a   Sattari, M ^b   Reza Nourani, M ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Antitumor effect; Cytokine; Monophosphoryl lipid A (MPL); Mouse fibrosarcoma; Staphylococcal enterotoxin B (SEB)

Indexed keywords

GAMMA INTERFERON; PHOSPHORYL LIPID A; STAPHYLOCOCCUS ENTEROTOXIN B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; FIBROSARCOMA; HISTOPATHOLOGY; MOUSE; NONHUMAN; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL LINE, TUMOR; ENTEROTOXINS; FEMALE; FIBROSARCOMA; FLOW CYTOMETRY; INTERFERON-GAMMA; INTERLEUKIN-2; LIPID A; MICE; MICE, INBRED BALB C; SPLEEN; SUPERANTIGENS; T-LYMPHOCYTE SUBSETS;

EID: 77954401616     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Stiles BG, Krakauer T. Staphylococcal enterotoxins: A purging experience in review, Part I. Clin Microbiol News Lett 2005; 27: 179-186.
2. Thomas P, John DF. Review Bacterial Superantigen. Clin Exp Immunol 2003; 133: 299-306.
3. Choi Y, Kotzin B, Herron L, Callahan J, Marrack P, Kappler J. Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. Proc Natl Acad Sci USA 1989; 86: 8941-8945.
4. Kappler J, Kotzin B, Herron L et al. V β-specific stimulation of human T cells by staphylococcal toxins. Science 1989; 244: 811-813. (Pubitemid 19163867)
5. Si S-Y, Hu P-Z, Huang Y-Y et al. Tumor cells with B7.1 and transmembrane anchored staphylococcal enterotoxin A generate effective antitumor immunity. Biochem Biophys Res Commun 2006; 347: 208-214.
6. Perabo FGE, Willert PL, Wirger A et al. Preclinical evaluation of superantigen (staphylococcal enterotoxin B) in the intravesical immunotherapy of superficial bladder cancer. Int J Cancer 2005; 115: 591-598. (Pubitemid 40656717)
7. Dalpke AH, Heeg K. Synergistic and antagonistic interactions between LPS and superantigens. J Endotoxin Res 2003; 9: 52-54.
8. Ostrand-Rosenberg S. Tumor immunotherapy: The tumor cell as antigen-presenting cell. Curr Opin Immunol 1994; 6: 722-727.
9. Shimizu M, Matsuzawa A, Takeda Y. A novel method for modification of tumor cells with bacterial superantigen with a heterobifunctional cross-linking agent in immunotherapy of cancer. Mol Biotechnol 2003; 25: 89-94. (Pubitemid 37100242)
10. Baldridge JR, Crane RT. Monophosphoryl Upid A (MPL) formulations for the next generation of vaccines. Methods 1999; 19: 103-107.
11. Alving CR. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiol 1993; 187: 430-446.
12. Thompson HS, Davies ML, Watts MJ. Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A. Vaccine 1998; 16: 1993-1999.
13. Neuzil KM, Johnson JE, Tang YW et al. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine 1997; 15: 525-532.
14. Moore A, McCarthy L, Mills KH. The adjuvant combination monophosphoryl lipid A and Q21 switches T cell responses induced with a soluble recombinant HIV protein from TH2 to TH1. Vaccine 1999; 17: 2517-2527. (Pubitemid 29314444)
15. Sasaki S, Tsuji T, Hamajima K et al. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1. Infect Immun 1997; 65: 3520-3528.
16. Fattom A, Li X, Cho YH et al. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides. Vaccine 1995; 13: 1288-1293.
17. Rickman LS, Gordon DM, Wistar R et al. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalene in malaria circumspororzoite protein vaccine. Lancet 1991; 337: 998-1001.
18. Hoffman SL, Edelman R, Bryan JP, Bryan JP, Schneider I, Davis J, et al. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalene as adjuvant. Am J Trop Med Hyg 1994; 51: 603-612.
19. Panthel K, Meinel KM, Domènecha VES et al. Prophylactic anti-tumor immunity against a murine fibrosarcoma triggered by the Salmonella type III secretion system. Microbes Infect 2006; 8: 2539-2546. (Pubitemid 44515152)
20. Ma W, Yu H, Wang Q, Jin H, Solheim J, Labhasetwar V. A novel approach for cancer immunotherapy: Tumor cells with anchored superantigen SEA generate effective antitumor immunity. J Clin Immunol 2004; 24: 294-301. (Pubitemid 39030677)
21. Mondai TK, Bhatta D, Biswas S, Pal P. Superantigen-induced apoptotic death of tumor cells is mediated by cytotoxic lymphocytes, cytokines, and nitric oxide. Biochem Biophys Res Commun 2002; 290: 1336-1342. (Pubitemid 34694452)
22. Macluskey M, Chandrachud ML, Pazouki S et al. Apoptosis, proliferation, and angiogenesis in oral tissues. Possible relevance to tumor progression. J Pathol 2000; 191: 368-375.
23. Kenneth AN, Joshua DIE, David SB, Jeffrey B. In vivo T-Cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor. Proc Natl Acad Sci USA 1991; 88: 1074-1078.
24. Fidler IJ, Kripke ML. Tumor cell antigenicity, host immunity, and cancer metastasis. Cancer Immunol Immunother 1980; 7: 201-205.
25. Kreitman RJ, Pastan I. Immunotoxins for targeted cancer therapy. Adv Drug Deliver Rev 1998; 31: 53-88. (Pubitemid 28191876)
26. Fischer H, Dohlsten M, Andersson U et al. Production of TNF-α and TNF-β by staphylococcal enterotoxin A activated human cells. J Immunol 1990; 144: 4663-4669. (Pubitemid 20224100)
27. Gjorloff A, Fischer H, Hedlund G et al. Induction of interleukin-1 in human monocytes by the superantigen staphylococcal enterotoxin A requires the participation of T-cells. Cell Immunol 1991; 137: 61-71.
28. Poste G, Fidler LI. The pathogenesis of cancer metastasis. Nature 1980; 283: 139-146.
29. Genevieve DB, Veronique M, Bernard P et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol 2000; 12: 807-815. (Pubitemid 30410453)
30. Goding JW. Use of staphylococcal protein as an immunological reagent. J Immunol Methods 1978; 20: 241-253.
31. Shimizu M, Yamamoto A, Nakano H, Matsuzawa A. Augmentation of antitumor immunity with bacterial superantigen, staphylococcal enterotoxin B-bound tumor cells. Cancer Res 1996; 56: 3731-3736. (Pubitemid 26272021)
32. Perabo FGE, Willert PL, Wirger A et al. Preclinical evaluation of superantigen (staphylococcal enterotoxin B) in the intravesical immunotherapy of superficial bladder cancer. Int J Cancer 2005; 115: 591-598. (Pubitemid 40656717)
33. Anne KW, Ulrich W, Harald R. Superantigen-Induced T Cell Death by Apoptosis: Analysis on a Single Cell Level and Effect of IFN-A and IL-4 Treatment. Int Arch Allergy Immunol 2000; 121: 215-223.
34. Lando PA, Hedlund G, Dohlsten M, Kalland T. Bacterial superantigens as anti tumour agents: Induction of tumour cytotoxicity in human lymphocytes by staphylococcal enterotoxin A. Cancer Immunol Immunother 1991; 33: 231-237.